» Articles » PMID: 2924083

Pharmacological Modulation of Paf-induced Rat Pleurisy and Its Role in Inflammation by Zymosan

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1989 Feb 1
PMID 2924083
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

1. The intrapleural injection of Paf-acether into rats caused, at 30 min, a marked exudation accompanied by a reduction in the pleural leucocyte count. At 6 h, the exudate volume had decreased and a significant increase in the total leucocyte count, particularly eosinophils was noted. 2. Two Paf-acether antagonists, WEB 2086 and 48740 RP abrogated the pleural leucopenia observed 30 min after Paf-acether administration, whereas the exudation was inhibited only by the former. Pleurisy was also reduced by about 60% with dexamethasone, by about 45% with BW 755C or LY 171883, a mixed cyclo-oxygenase/lipoxygenase inhibitor and a peptido-leukotriene antagonist respectively, and by about 30% with indomethacin, flurbiprofen or piroxicam. 3. Repeated daily intrapleural injections of Paf-acether led to a state of progressive desensitization to Paf-acether itself, whereas responsiveness to 5-hydroxytryptamine was maintained. In addition, the Paf-induced auto-desensitization was largely inhibited by WEB 2086. 4. Pleurisy induced by zymosan, but not by carrageenin, was significantly reduced in Paf-acether-desensitized animals. These results were consistent with those obtained with WEB 2086 which suppressed zymosan-induced but not carrageenin-induced pleurisy. 5. This study suggests that Paf-acether-induced pleurisy in the rat may be mediated by lipoxygenase arachidonic acid metabolites and that pleurisy induced by zymosan, but not by carrageenin, is largely dependent upon Paf-acether.

Citing Articles

The Enigma of Eosinophil Degranulation.

Fettrelet T, Gigon L, Karaulov A, Yousefi S, Simon H Int J Mol Sci. 2021; 22(13).

PMID: 34209362 PMC: 8268949. DOI: 10.3390/ijms22137091.


Methyl gallate attenuates inflammation induced by Toll-like receptor ligands by inhibiting MAPK and NF-Κb signaling pathways.

Correa L, Seito L, Manchope M, Verri Jr W, Cunha T, Henriques M Inflamm Res. 2020; 69(12):1257-1270.

PMID: 33037469 DOI: 10.1007/s00011-020-01407-0.


Eosinophil recruitment and activation: the role of lipid mediators.

Luna-Gomes T, Bozza P, Bandeira-Melo C Front Pharmacol. 2013; 4:27.

PMID: 23525348 PMC: 3605515. DOI: 10.3389/fphar.2013.00027.


Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.

Kolaczkowska E, Shahzidi S, Seljelid R, van Rooijen N, Plytycz B Inflammation. 2002; 26(2):61-71.

PMID: 11989789 DOI: 10.1023/a:1014837110735.


In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67).

Wang C, Bozza P, Barbashov S, Sauty A, Nicholson-Weller A Clin Exp Immunol. 1999; 117(2):261-8.

PMID: 10444256 PMC: 1905347. DOI: 10.1046/j.1365-2249.1999.00962.x.


References
1.
Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona G . Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol. 1987; 139(7):2439-46. View

2.
Braquet P, Touqui L, Shen T, Vargaftig B . Perspectives in platelet-activating factor research. Pharmacol Rev. 1987; 39(2):97-145. View

3.
Lellouch-Tubiana A, Lefort J, Simon M, Pfister A, Vargaftig B . Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis. 1988; 137(4):948-54. DOI: 10.1164/ajrccm/137.4.948. View

4.
Jancar S, Braquet P, Sirois P . Interactions of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions. Braz J Med Biol Res. 1987; 20(5):487-94. View

5.
Lefort J, Sedivy P, Desquand S, Randon J, Coeffier E, Floch A . Pharmacological profile of 48740 R.P., a PAF-acether antagonist. Eur J Pharmacol. 1988; 150(3):257-68. DOI: 10.1016/0014-2999(88)90006-4. View